RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
 Clinical Trials
 Infectious Diseases
  Anorexia Nervosa
  Child Psychiatry
  Forensic Psychiatry
  Mood Disorders
  Peri-Natal Psychiatry
  Personality Disorders
  Sleep Disorders
  Substance Abuse
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Neuropsychopharmacology Amphetamine Channel

subscribe to Amphetamine newsletter
Latest Research : Psychiatry : Substance Abuse : Amphetamine

   EMAIL   |   PRINT
Bupropion as Methamphetamine Addiction Treatment Hold Promise

Nov 26, 2005 - 4:17:00 PM
"Bupropion's novel effect on the brain is what makes this line of research so promising"

[RxPG] A new study led by researchers at UCLA's Semel Institute suggests the antidepressant bupropion may help treat methamphetamine addiction. No medications presently are approved for treating methamphetamine addicts.

Appearing Nov. 23 as an advance online publication of the peer-reviewed journal Neuropsychopharmacology, the study finds bupropion blunts the methamphetamine "high" and reduces cravings prompted by visual cues such as ambient drug use.

The research team hypothesizes that bupropion reduces the effects of methamphetamine by preventing the drug from entering brain cells, where methamphetamine can produce release of neurotransmitters that cause feelings of euphoria.

The study is the first to examine the effectiveness of bupropion for treating methamphetamine addiction in humans. A multisite Phase II clinical trial led by UCLA researchers is in progress.

"Finding new, effective ways to treat methamphetamine addiction is a key component of bringing the ongoing epidemic of abuse under control," said Dr. Thomas F. Newton, the study's principal investigator and professor at the Semel Institute for Neuroscience and Human Behavior.

"Bupropion's novel effect on the brain is what makes this line of research so promising," added Newton, who also is a professor of psychiatry and biobehavioral sciences at the David Geffen School of Medicine at UCLA. "These findings may point the way toward medications with even greater potential to be helpful."

Twenty of 26 participants enrolled in the project completed the study. Participants were active methamphetamine users between ages 18 and 45. Researchers randomly assigned each participant to receive treatment either with a placebo — an inactive ingredient such as a sugar pill — or bupropion.

Each participant received a series of three intravenous doses of methamphetamine as the study began and a second, identical series of doses six days after treatment with placebo or bupropion began.

Using a variety of subjective rating scales and questionnaires, participants reported on the subjective effects of the methamphetamine use at baseline and again after treatment with placebo or bupropion. Subjects who took the medication reported a lesser high after treatment.

Each set of research subjects reported similarly on cravings, both at baseline and after treatment, after watching a video with actors portraying methamphetamine use. Subjects who took bupropion reported less intense craving.

Publication: Peer-reviewed journal Neuropsychopharmacology
On the web: www.ucla.edu 

Advertise in this space for $10 per month. Contact us today.

Related Amphetamine News
Ecstasy use could harm brain
Discovery could lead to more effective treatments for amphetamine abuse and brain disease
Bupropion as Methamphetamine Addiction Treatment Hold Promise
Teenage drug use can lead to adult heart attack
Distinct differences in onset, pattern and duration of cocaine and methamphetamine 'highs'

Subscribe to Amphetamine Newsletter

Enter your email address:

 Additional information about the news article
The study was funded by the National Institute on Drug Abuse. Other members of the research team included Richard De La Garza II and Timothy Fong of UCLA's Semel Institute and Geffen School of Medicine; John D. Roache and Christopher L. Wallace of the University of Texas Health Science Center at San Antonio; and Shou-Hua Li, Ahmed Elkashef, Nora Chiang and Roberta Kahn at the National Institute on Drug Abuse in Bethesda, Md.
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)